Matthew B. Harms, MD, on Gene Therapy’s Potential to Address Unmet Needs in ALS

Video

The associate professor of neurology at Columbia University spoke about the current and future treatment landscape in ALS.

“Coupling those [currently approved] medications to hopefully slow down the disease, with physical therapy, breathing interventions, nutritional interventions—things that we know improve quality of life and help keep patients alive for longer—are the mainstays of ALS treatment now, but we all recognize that those are inadequate and they're not bringing about the changes in life expectancy and functionality for our patients [that we would like to see]. And so, we're hopeful that gene therapies may be a breakthrough in that respect.”

While there are several approved medications currently available for amyotrophic lateral sclerosis (ALS), significant unmet needs remain for patients with the disease. Several gene therapies are currently in development which are intended to address these unmet needs.

Matthew B. Harms, MD, associate professor of neurology, Columbia University, and medical consultant and care center director, Muscular Dystrophy Association (MDA), chaired a session covering this topic entitled “Gene Therapy in ALS” at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, held in Dallas, Texas, March 19-22, 2023.

In an interview with CGTLive™, Harms spoke about the current standards of care for patients with ALS and the potential of gene therapy to address needs not currently met by these options. He noted that the earliest breakthroughs are likely to come about for patients with identifiable gene mutations related to ALS, such as SOD1 and C9orf72. Harms also discussed the implications for patients if any of the gene therapies currently in development for ALS are approved, emphasizing that an approval could inspire increased interest in ALS research from neuromuscular neurologists. In addition, he touched on his thoughts on the MDA conference in general, pointing out that it was an opportunity for clinicians working in the ALS gene therapy space to learn from neuromuscular disease experts specializing in other diseases for which gene therapies are in development.

Read more coverage of the 2023 MDA Conference here.

Editor’s Note: Harms disclosed that he has board memberships in the Northeast ALS Consortium and Muscular Dystrophy Association. He also disclosed consultancies or paid advisory boards for Biogen and Ionis; grants/research funding pending for Biogen, Ionis, and UniQure; and grants received/research funding for Biogen and Ionis.

Recent Videos
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
© 2024 MJH Life Sciences

All rights reserved.